scholarly journals Pembrolizumab in Non-Small Cell Lung Cancer: The Role of Restricted Mean Survival Time in Estimating The Long-Term Survival Benefit

2021 ◽  
Vol 4 (1) ◽  
Author(s):  
Messori Andrea ◽  
Chiumente Marco ◽  
Mengato Daniele
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Survival Benefit ◽  
Small Cell ◽  
Small Cell Lung ◽  
Term Survival ◽  
Mean Survival Time ◽  
Restricted Mean Survival Time

scholarly journals Progression-Free Survival: An Important Prognostic Marker for Long-Term Survival of Small Cell Lung Cancer

2014 ◽  
Vol 76 (5) ◽  
pp. 218 ◽  
Author(s):  
Myoung-Rin Park ◽  
Yeon-Hee Park ◽  
Jae-Woo Choi ◽  
Dong-Il Park ◽  
Chae-Uk Chung ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Prognostic Marker ◽  
Cell Lung Cancer ◽  
Progression Free Survival ◽  
Small Cell ◽  
Small Cell Lung ◽  
Term Survival ◽  
Free Survival

scholarly journals Long-term survival of robotic lobectomy for non-small cell lung cancer: a literature review

2020 ◽  
Vol 2020 ◽  
Author(s):  
Sara Ricciardi ◽  
Federico Davini ◽  
Carmelina C. Zirafa ◽  
Gaetano Romano ◽  
Franca M. A. Melfi
Keyword(s):  
Lung Cancer ◽  
Literature Review ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Term Survival ◽  
Long Term Survival

Improvement of long-term survival in extensive small-cell lung cancer.

1988 ◽  
Vol 6 (7) ◽  
pp. 1161-1169 ◽  
Author(s):  
D V Jackson ◽  
L D Case ◽  
P J Zekan ◽  
B L Powell ◽  
R D Caldwell ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Objective Response ◽  
Complete Response ◽  
Treated Group ◽  
Small Cell ◽  
Small Cell Lung ◽  
Term Survival

The effect of adding the epipodophyllotoxin etoposide (VP-16-213) to a standard chemotherapy regimen for patients with extensive stage small-cell lung cancer was evaluated during a randomized trial. Chemotherapy consisted of vincristine, doxorubicin, and cyclophosphamide (VAC) alone or with etoposide (EVAC). Of 139 patients enrolled, 136 patients were eligible for study and all but five were evaluable for response. The overall objective response was 46% in the VAC group v 70% in the etoposide-treated group (P = .008) with complete response (CR) rates of 12% v 29%, respectively (P = .030). Although the time to the observation of disease progression was significantly longer in the group of patients receiving etoposide (9.6 v 6.5 months, P = .010), overall survival was similar; this was probably due to administration of other agents including etoposide at the time of VAC failure. However, there were noteworthy differences in long-term (greater than or equal to 2 year) survival. Whereas only four (6%) patients treated with VAC lived 2 years, 11 (16%) of the etoposide-treated group did so (P = .100). Two-year failure-free survival was attained in one (2%) of the VAC patients and eight (11%) of the patients treated with etoposide (P = .034). Long-term survivorship, heretofore usually reported in patients with limited stage disease after a variety of treatments, may be possible with this drug combination in the setting of extensive disease.

Sign in / Sign up

Export Citation Format

Share Document